Breaking News

Goodwin Names COO

By Gil Roth | September 16, 2013

Lee rejoins bio-CMO

SooYoung Lee, Ph.D. has returned to Goodwin Biotechnology as chief operating officer. Dr. Lee will report to the newly appointed chief executive officer, Karl Pinto, and will oversee all aspects of Goodwin's contract manufacturing operations. He previously served at Goodwin as senior vice president, operations from 2010 to 2011.

Dr. Lee has had a multi-decade career in the biological industry. He has held several leadership positions at such biopharma companies and CMOs as SAIC – Frederick, Schering-Plough Research Institute, Wyeth – Lederle Vaccines, AppTec, Neose Technologies and Genencor. He also has extensive experience in international biotechnology operations, having established and served as the director of the Biopharmaceutical Manufacturing Technology Center (BMTC) in Singapore. As a senior member, he helped establish the International Vaccine Institute (IVI) in Seoul, Korea.

"SooYoung's experiences in process development, tech transfer and GMP manufacturing along with strategic planning and execution will help ensure the delivery of the highest quality services and products that are in compliance with cGMP to our clients, ranging from the smallest biotech start-ups to large biopharma companies," noted Mr. Pinto. "With this significant addition, we are poised to take the company to new heights."
blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent